文献速递前列腺癌

基于MRI的前列腺癌风险计算器的临床影响:系统综述与荟萃分析

Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: a systematic review and meta-analysis.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2025-08-26

该系统综述与荟萃分析纳入16项研究,比较基于MRI的风险计算器与传统临床模型对前列腺癌的诊断区分能力。基于MRI的风险计算器对临床显著前列腺癌的AUC为0.84(95%CI: 0.81-0.86),优于临床模型的0.76(95%CI: 0.73-0.79);对全部前列腺癌的AUC为0.81(95%CI: 0.78-0.84),优于临床模型的0.74(95%CI: 0.68-0.79)。结论认为基于MRI的风险计算器可提高诊断准确性,有望减少不必要活检。

要点

  • 基于MRI的风险计算器对临床显著前列腺癌的AUC为0.84,高于临床模型的0.76。
  • 对全部前列腺癌,基于MRI的风险计算器AUC为0.81,高于临床模型的0.74。
  • 基于MRI的风险计算器有望减少不必要的前列腺穿刺活检。

核心结论

  • 基于MRI的风险计算器提高了前列腺癌的诊断准确性,有潜力减少不必要的活检并优化医疗资源。

研究设计与样本

  • 系统检索Embase、Medline、Scopus、Cochrane Library和Web of Science数据库,评估基于MRI的风险计算器的区分能力。
  • 最终纳入16项研究,采用AUC进行荟萃分析,合并AUC估计值并评估异质性。

主要发现

  • 对临床显著前列腺癌,基于MRI的风险计算器AUC为0.84(95%CI: 0.81-0.86),临床模型为0.76(95%CI: 0.73-0.79)。
  • 对全部前列腺癌,基于MRI的风险计算器AUC为0.81(95%CI: 0.78-0.84),临床模型为0.74(95%CI: 0.68-0.79)。
  • 合并的logit(AUC)差值:临床显著前列腺癌为0.49单位,全部前列腺癌为0.37单位。
  • 观察到高度异质性,可能源于前列腺癌的变异性;31%的研究存在高或不明确的偏倚风险。

临床怎么用

  • 基于MRI的风险计算器可整合入临床实践,辅助前列腺癌诊断决策。
  • 其应用可能减少不必要的穿刺活检并优化医疗资源利用。

局限性

  • 研究间存在高度异质性,可能影响结果的可推广性。
  • 31%的研究具有高或不明确的偏倚风险,可能影响结论的可靠性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer (PCa) is the second most common cancer among men worldwide. Current diagnostic methods often lack sufficient sensitivity and specificity, leading to unnecessary biopsy. With growing use of MRI and EAU guideline recommendations, this review synthesised evidence on MRI-based risk calculators (RCs) for PCa diagnosis and compared their performance with traditional clinical RCs. METHODS: A systematic search of Embase, Medline, Scopus, Cochrane Library, and Web of Science databases assessed the discriminatory ability of MRI-based RCs using Area Under the Curve (AUC). A meta-analysis was conducted to pool AUC estimates, assess heterogeneity, and compare the differences in discriminatory ability. RESULTS: Of 2049 papers, 16 met the inclusion criteria. MRI-based RCs showed increased discrimination, with an AUC of 0.84 (95% CI: 0.81-0.86) for clinically significant PCa (csPCa), compared to 0.76 (95% CI: 0.73-0.79) for clinical models, and an AUC of 0.81 (95% CI: 0.78-0.84) for all PCa, compared to 0.74 (95% CI: 0.68-0.79). The pooled logit(AUC) difference was 0.49 units for csPCa and 0.37 units for all PCa. High heterogeneity was noted, likely due to PCa variability, and 31% of the studies had a high or unclear risk of bias, potentially affecting generalisability. CONCLUSIONS: MRI-based RCs improve the diagnostic accuracy for PCa with the potential to reduce unnecessary biopsies and optimise healthcare resources, thereby supporting their integration into clinical practice.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Courtney O'Toole C, Boakye NF, Hannigan A, et al. Clinical impact of MRI-based risk calculators for prostate cancer diagnosis: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025. PMID: 40858922. doi:10.1038/s41391-025-01014-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。